奥美沙坦对高血压患者血清hs-CRP、ICAM-1及sCD40L的影响

The Influence of Olmesartan on hs-CPR,ICAM-1 and sCD40L in Hypertension

目的观察高血压病人奥美沙坦治疗前、后血清hs-CRP、ICAM-1、sCD40L的浓度变化,探讨奥美沙坦在有效降压的同时是否具有抗炎作用。方法选择我院门诊新发现或未经长期降压治疗的轻、中度高血压病人53例(男41例,女12例),均符合WHO/ISA1999年的诊断标准,平均年龄(53．23±7．60)岁,所有人选者抽取空腹12 h静脉血,用ELISA方法测定血清hs-CRP、ICAM-1、sCD40L的水平,均口服奥美沙坦20 mg/d,4周后若舒张压＞90 mm Hg,剂量加倍40 mg/d,共服药8周,8周后抽血。所有入选者均测血压、血脂、血糖,服药8周后重复测定以上所有指标。结果(1)高血压病人用药前、后血脂、血糖均无差异(P＞0．05),具有可比性;治疗后血压有明显下降(P＜0．01);(2)高血压用药后hs-CRP、ICAM-1、sCD40L明显下降(分别为1．66±1．34 mg/L versus 2．37±1．81 mg/L,P＜0．01;152．25±50．72 ng/ml Versus 204．86±49．33 ng/ml,P＜0．01;3298．50±1309．01 pg/ml versus 5191．72±1144．63 pg/ml,P＜0．01)。结论奥美沙坦在有效降压的同时具有抗炎作用。

Objective The aim of the study was To study the influence of Olmesartan on hs-CRP, ICAM-1 and sCD40L in hypertension, so we can estimate whether Olmesartan has Anti-inflammatory action. Methods Patients （ 41 male, 12 females） with mild-to-moderate hypertension,according to the WHO/ISA criteria, were eligible for inclusion. Serum was assayed for hs-CRP, ICAM-1 and sCD40L using by Enzyme-Linked Immunosorbent Assay （ELISA）. All patients were started on drug therapy for 8 weeks. The initial olmesartan dose was 20 mg once a day. The dosage was increased to 40 mg after 4 weeks if diastolic blood pressure （DBP） 〉 90 mm Hg. Blood pressure, Serum glucose and lipid were measured. Above all measurements were evaluated again by the same methods after 8 weeks. Results After 8 weeks of treatment, olmesartan reduced blood pressure compared with baseline （ P 〈 0.01 ）. There was a significant （ 1.66 ± 1.34 mg/ L versus 2.37 ± 1.81mg/L,152.25 ±50.72 ng/ml versus 204.86±49.33 ng/ml, 3298.50 ± 1309.01 pg/ ml versus 5191.72 ± 1144.63 pg/ml, P 〈0.01 for all comparisons, respectively） decrease in serum hs- CRP, ICAM-1 and sCD40L in hypertensive patients after using Olmesartan. Conclusion Olmesartan had anti-inflammatory effect as well as anti-hyoertension.